Movement Alert｜Summit Therapeutics PLC falls 5.24% in Pre-Market Trading, advances late-stage ivonescimab biliary tract cancer study

Market Focus10-22

On October 22, Summit Therapeutics PLC fell 5.24% in Pre-Market Trading, with shares at $15.0 and turnover of $205.3 thousand.

The move followed the company’s announcement that it will collaborate with the ECOG-ACRIN Cancer Research Group on a phase 2/3 trial evaluating ivonescimab as a first-line treatment for advanced biliary tract cancer.

The study will compare ivonescimab plus gemcitabine and cisplatin chemotherapy against pembrolizumab or durvalumab combined with the same chemotherapy, with overall survival as the primary endpoint. Trial sites are expected to begin opening in the fourth quarter. The update extends Summit Therapeutics PLC’s broader ivonescimab development push after recent kidney cancer study initiation and the previously completed $2 billion strategic equity investment from AstraZeneca.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment